Tag: SN-38
Gilead Agrees to Collaborate on the Strata Precision Indications for Approved...
Gilead Sciences and Strata Oncology have signed an agreement in which Gilead has agreed to collaborate on the Strata Precision Indications for Approved THerapies (Strata PATH™; NCT05097599) study by providing sacituzumab govitecan-hziy (Trodelvy®) for eligible patients with cancer.
Sacituzumab Govitecan Increases PFS for Patients With Most Common Type of...
Treatment with sacituzumab govitecan (Trodelvy®; Gilead Sciences), an antibody-drug conjugate (ADC), resulted in longer progression-free survival (PFS) compared to physician’s choice of chemotherapy in...
ESMO 2020: Sacituzumab Govitecan Shows Encouraging Early-Stage Clinical Results in Brain...
A clinical trial (NCT03995706) studying the extent by which sacituzumab govitecan (Trodelvy™; Immunomedics) is able to get into the brain and treat patients with...
Everest Medicines to Initiate a Registration Study in China for Sacituzumab...
China-based Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative products, address critical unmet medical needs for patients in Greater China and...
FDA Grants Accelerated Approval for Sacituzumab Govitecan in Metastatic Triple-negative Breast...
The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan* (Trodelvy™; Immunomedics) for the treatment of adult patients with metastatic triple-negative breast cancer...
FDA Accepts Resubmission of Biologics License Application for Sacituzumab Govitecan
Earlier today the U.S. Food and Drug Administration (FDA) confirmed that it has accepted Immunomedics' Resubmission of the Biologics License Application (BLA) for sacituzumab...
Immunomedics Resubmits BLA for Sacituzumab Govitecan
In a statement earlier today, Immunomedics confirmed that the company resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)...
Immunomedics and Everest Signs License Agreement for Sacituzumab Govitecan
In late April 2019 Immunomedics and Everest Medicines II Limited, a C-Bridge Capital-backed biopharmaceutical company, confirmed that the companies had signed an exclusive license...
New ADC Payload Platform – Synaffix Launches toxSYN™
The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...
Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...
Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...
